The efficacy of DPP-4 inhibitors and alpha glucosidase inhibitors for type 2diabetes
Not Applicable
Completed
- Conditions
- Patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000011788
- Lead Sponsor
- ational Center for Global Health and Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe liver dysfunction or renal dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Markers for glucose metabolism and incretin related hormones
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie DPP-4 inhibition in type 2 diabetes management?
How do alpha glucosidase inhibitors compare to DPP-4 inhibitors in glycemic control for type 2 diabetes patients?
Which biomarkers correlate with response to DPP-4 or alpha glucosidase inhibitors in Japanese type 2 diabetes populations?
What are the long-term adverse event profiles of DPP-4 inhibitors versus alpha glucosidase inhibitors in type 2 diabetes treatment?
How do DPP-4 inhibitors and alpha glucosidase inhibitors interact with other antidiabetic agents like metformin or GLP-1 receptor agonists in type 2 diabetes therapy?